Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anwesha Das has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    [BMIM]OAc promoted one-pot synthesis of pyrazolo[4′,3′:5,6]pyrido[2,3- d ]pyrimidin-5-ones and their antimicrobial activity

    by Savan S. Bhalodiya, Mehul P. Parmar, Shana Balachandran, Chirag D. Patel, Arijit Nandi, Anwesha Das, Madan Kumar Arumugam, Hitendra M. Patel

    A one-pot method was developed for synthesizing pyrazolo[4′,3′:5,6]pyrido[2,3-d]pyrimidin-5-ones using the recyclable ionic liquid catalyst [BMIM]OAc in ethanol under reflux conditions. This approach achieved high yields (76–95%) across various substrates along with straightforward product isolation and catalyst recyclability. The synthesized compounds 4(a–l) were tested for antimicrobial activity against Gram-positive and Gram-negative bacteria, and fungal strains. Notably, compounds 4c and 4e showed strong antibacterial effects against S. aureus (MIC: 8 µg mL−1), while 4a, 4b, and 4f effectively inhibited E. coli (MIC: 8 µg mL−1). Compound 4l exhibited notable antifungal activity against C. albicans (MIC: 8 µg mL−1), outperforming the standard drugs. Cytotoxicity assessment on HEK293 cells revealed low toxicity in most derivatives (IC50 > 50 µM), with halogenated analogs (4c, 4e) displaying moderate activity but remaining less toxic than doxorubicin. Molecular docking and dynamics simulations confirmed stable interactions of key compounds (4c, 4e, 4f) with bacterial Tet repressor class D and fungal sterol 14-α demethylase, consistent with experimental data. Overall, this ionic liquid-catalyzed approach provides an efficient route to bioactive heterocycles with promising antimicrobial and anticancer potential.


  • Tyrosine Kinase as the Therapeutic Target for Neurodegenerative Diseases

    by Nandita Mandal, Avijit Bej, Anwesha Das, Arijit Nandi

    Treatment based on the inhibition of tyrosine kinases can provide relief to patients with severe neurodegenerative phenomena, for example, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. All these conditions involve ongoing neuronal disruptions and neuro-degeneration, sharing several common traits: the build-up of abnormal protein aggregates, oxidative stress, mitochondrial dysfunction, DNA damage, neurotrophin irregularities, and persistent neuro-inflammation. Pathways participating in neurodegenerative diseases' progression and development, accompanied by the expression of biomarkers, are dependent on the activities of proteins called tyrosine kinases and phosphatases.

  • A study of Leonurine in chemically induced IgA nephropathy on Sprague Dawley rats

    by Arnab Chowdhury, Kousik Maparu, Arijit Nandi, Anwesha Das, Himangshu Sekhar Maji, Rajiv Jash

    IgAN, the most common primary glomerulonephritis, causes nephritic symptoms like blood and protein in urine, elevated creatinine, and chronic kidney inflammation. In this research, we tried to examine the role of phytochemical Leonurine in mitigating fibrosis and inflammation in IgAN rat model through TGF-β/SMAD signalling pathway regulation. Thirty Sprague Dawley rats were randomly assigned to treatment-, control-, and IgAN-induced groups. The treatment-group received Leonurine as a drug post-induction of IgAN. Immunofluorescence and histopathology confirmed the disease model, showing increased fibrosis markers and renal IgA deposits. The model was induced using BSA, CCl4, and LPS. Ten-week leonurine-treatment reduced kidney injury markers, BUN, and serum creatinine in rats without affecting liver enzymes, ameliorating nephritic syndrome without hepatotoxicity. It preserved glomerular diameter and lowered profibrotic and proinflammatory markers. The result indicated that Leonurine ameliorates IgA nephropathy symptoms in rats by reducing inflammation and fibrosis, possibly through TGF-β/SMAD pathways, leading to decreased nephritic symptoms.

  • Design and synthesis of novel quinazolinone-based pyruvate kinase M2 activators as selective inhibitors of oral cancer cells

    by Bhagyashri Rathod, Swarali Joshi, Siddulu Regu, K.V.N.S. Manikanta, Hansal Kumar, Samdisha Dubey, Arnab Chowdhury, Raisa Parveen Shaikh, Anwesha Das, Sagarkumar Patel, et al.


  • Open Access

    Phenylthiazolidin-4-one piperazine Conjugates: Design, Synthesis, anticancer and antimicrobial studies

    by Dalbir Singh, Rajiv Patel, Amit Aggarwal, Anwesha Das, Saurabh Sharma, Birasen Behera, Rajashree Panigrahy, Amanda R. Kirane, Harsha Kharkwal, Piyush Kumar, et al.


  • Effectiveness of estrogen and its derivatives over dexamethasone in the treatment of COVID-19

    by Darakhshan Parveen, Anwesha Das, Shaista Amin, M. Mumtaz Alam, Mymoona Akhter, Mohammad Ahmed Khan, Ruhi Ali, Tarique Anwer, Khursheed A. Sheikh, Faizul Azam, et al.

    Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus and dexamethasone is a glucocorticoid widely used for its treatment. Dexamethasone is not used in non-severe cases due to its immunosuppressant action. So, considering this, Estrogen and Estetrol were tested for the treatment of COVID-19 as they all possess a common steroid ring and dislike dexamethasone, they are immunoenhancer. Virtual screening of test ligands was performed through molecular docking, MM-GBSA, simulations, in silico ADMET and drug-likeness prediction to identify their potential to inhibit the effects of SARS-CoV-2. Results showed that test ligands possess drug-like properties and they are safe as drug candidates. The protein-ligand interaction study revealed that they bind with the amino acid residues at the active site of the target proteins and the test ligands possess better binding potential than Dexamethasone. With protein Mpro, Estetrol and Estrogen showed docking score of −7.240 and −5.491 kcal/mol, and with protein ACE2, Estetrol and Estrogen showed docking score of −5.269 and −4.732 kcal/mol, respectively. Further, MD Simulation was carried out and most of the interactions of molecular docking are preserved during simulation. The prominent interactions that our test ligands showed during MD Simulation are similar to drugs that possess in vitro anticovid activity as shown in recent studies. Hence, our test ligands possessed potential for anticovid activity and they should be further tested through in vitro and in vivo studies for their activity against COVID-19. Communicated by Ramaswamy H. Sarma


  • Open Access

    Enhydra fluctuans Lour. aqueous extract inhibited the growth of calcium phosphate crystals: An in vitro study

    by Bornika Chattaraj, Arijit Nandi, Anwesha Das, Arun Baidya, Sourav Mahata, Aritra Chowdhury, Soumya Mitra, Sumon Roy, Subrata Chakraborty, Yadu Nandan Dey


  • Open Access

    The Abundant Phytocannabinoids in Rheumatoid Arthritis: Therapeutic Targets and Molecular Processes Identified Using Integrated Bioinformatics and Network Pharmacology

    by Arijit Nandi, Anwesha Das, Yadu Nandan Dey, Kuldeep K. Roy

    The endocannabinoid system consists of several phytocannabinoids, cannabinoid receptors, and enzymes that aid in numerous steps necessary to manifest any pharmacological activity. It is well known that the endocannabinoid system inhibits the pathogenesis of the inflammatory and autoimmune disease rheumatoid arthritis (RA). To the best of our knowledge, no research has been done that explains the network-pharmacology-based anti-rheumatic processes by focusing on the endocannabinoid system. Therefore, the purpose of this study is to further our understanding of the signaling pathways, associated proteins, and genes underlying RA based on the abundant natural endocannabinoids. The knowledge on how the phytocannabinoids in Cannabis sativa affect the endocannabinoid system was gathered from the literature. SwissTarget prediction and BindingDB databases were used to anticipate the targets for the phytocannabinoids. The genes related to RA were retrieved from the DisGeNET and GeneCards databases. Protein–protein interactions (high confidence > 0.7) were carried out with the aid of the string web server and displayed using Cytoscape. The Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway analysis was used to perform enrichment analyses on the endocannabinoid–RA common targets. ShinyGO 0.76 was used to predict the biological processes listed in the Gene Ontology (GO) classification system. The binding affinity between the ligand and the receptors was precisely understood using molecular docking, induced-fit docking, and a molecular dynamics simulation. The network pharmacology analyses predicted that processes like response to oxygen-containing compounds and peptodyl-amino acid modification are related to the potential mechanisms of treatment for RA. These biological actions are coordinated by cancer, neuroactive ligand–receptor interaction, lipids and atherosclerosis, the calcium signaling pathway, and the Rap1 signaling pathway. According to the results of molecular docking, in the context of RA, phytocannabinoids may bind to important target proteins such PIK3CA, AKT1, MAPK9, PRKCD, BRAF, IGF1R, and NOS3. This entire study predicted the phytocannabinoids’ systemic biological characteristics. Future experimental research is needed, however, to confirm the results so far.